血管免疫母细胞性T细胞淋巴瘤的诊治进展与展望

Review of advances in diagnosis and treatment of angioimmunoblastic T cell lymphoma

血管免疫母细胞性T细胞淋巴瘤(angioimmunoblastic T-cell lymphoma,AITL)是一种高度侵袭性的T细胞淋巴瘤亚型,目前尚无标准治疗方案,患者的生存状况不容乐观。AITL显著的疾病异质性和复杂的发病机制,以及诊断和治疗上仍未被满足的医疗需求都使得该疾病备受关注,对AITL进行早期精准诊断和及时有效治疗对改善患者预后至关重要。在病理组织学的基础上,新兴的分子技术和流式细胞术正逐步提高AITL早期识别的准确性。基于传统化疗效果有限,当前研究正聚焦于靶向治疗和免疫疗法的开发。本文就AITL的发病机制、诊断方法以及治疗策略等方面进行述评,展望未来在该领域的研究方向。

Angioimmunoblastic T-cell lymphoma(AITL)is a highly aggressive subtype of T-cell lymphoma with no standard treatment,resulting in poor survival outcomes for patients.With its high heterogeneity,complex pathogenesis and unmet needs in diagnosis and treatment,this disease has received considerable attention.Accurate diagnosis and effective treatment are essential to improve patient prognosis.Emerging molecular technologies and flow cytometry are progressively improving the accuracy of early detection of AITL,building on traditional histopathology.Given the limited efficacy of conventional chemotherapy,current research is focused on the development of targeted therapies and immunotherapies.This article reviewed the pathogenesis,diagnostic methods,and treatment strategies for AITL and explored future research directions in this field.